176 related articles for article (PubMed ID: 17057558)
1. Managing cancer pain and symptoms of outpatients by rotation to sustained-release hydromorphone: a prospective clinical trial.
Wirz S; Wartenberg HC; Elsen C; Wittmann M; Diederichs M; Nadstawek J
Clin J Pain; 2006; 22(9):770-5. PubMed ID: 17057558
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine.
Wirz S; Wittmann M; Schenk M; Schroeck A; Schaefer N; Mueller M; Standop J; Kloecker N; Nadstawek J
Eur J Pain; 2009 Aug; 13(7):737-43. PubMed ID: 18977159
[TBL] [Abstract][Full Text] [Related]
3. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
4. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety profile of a single dose of hydromorphone compared with morphine in older adults with acute, severe pain: a prospective, randomized, double-blind clinical trial.
Chang AK; Bijur PE; Baccelieri A; Gallagher EJ
Am J Geriatr Pharmacother; 2009 Feb; 7(1):1-10. PubMed ID: 19281935
[TBL] [Abstract][Full Text] [Related]
6. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
Clemens KE; Klaschik E
Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302
[TBL] [Abstract][Full Text] [Related]
7. Opioid rotation from morphine to fentanyl in delirious cancer patients: an open-label trial.
Morita T; Takigawa C; Onishi H; Tajima T; Tani K; Matsubara T; Miyoshi I; Ikenaga M; Akechi T; Uchitomi Y;
J Pain Symptom Manage; 2005 Jul; 30(1):96-103. PubMed ID: 16043013
[TBL] [Abstract][Full Text] [Related]
8. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
9. [Controlled-release hydromorphone in elderly patients with severe pain of different etiologies. Results of an observational study].
Junker U; Figge V
MMW Fortschr Med; 2005 Oct; 147 Suppl 3():91-6. PubMed ID: 16261943
[TBL] [Abstract][Full Text] [Related]
10. Opioid switch in palliative care, opioid choice by clinical need and opioid availability.
Müller-Busch HC; Lindena G; Tietze K; Woskanjan S
Eur J Pain; 2005 Oct; 9(5):571-9. PubMed ID: 16139186
[TBL] [Abstract][Full Text] [Related]
11. Modeling the economic and health consequences of managing chronic osteoarthritis pain with opioids in Germany: comparison of extended-release oxycodone and OROS hydromorphone.
Ward A; Bozkaya D; Fleischmann J; Dubois D; Sabatowski R; Caro JJ
Curr Med Res Opin; 2007 Oct; 23(10):2333-45. PubMed ID: 17697453
[TBL] [Abstract][Full Text] [Related]
12. Oral versus intravenous opioid dosing for the initial treatment of acute musculoskeletal pain in the emergency department.
Miner JR; Moore J; Gray RO; Skinner L; Biros MH
Acad Emerg Med; 2008 Dec; 15(12):1234-40. PubMed ID: 18945240
[TBL] [Abstract][Full Text] [Related]
13. Normal-release oral morphine starting dose in cancer patients with pain.
Ripamonti CI; Campa T; Fagnoni E; Brunelli C; Luzzani M; Maltoni M; De Conno F;
Clin J Pain; 2009 Jun; 25(5):386-90. PubMed ID: 19454871
[TBL] [Abstract][Full Text] [Related]
14. Opioid equianalgesic conversion: the right dose.
Brant JM
Clin J Oncol Nurs; 2001; 5(4):163-5. PubMed ID: 12690618
[TBL] [Abstract][Full Text] [Related]
15. The role of OROS hydromorphone in the management of cancer pain.
Gardner-Nix J; Mercadante S
Pain Pract; 2010; 10(1):72-7. PubMed ID: 19863749
[TBL] [Abstract][Full Text] [Related]
16. A randomized, open, parallel group, multicenter trial to investigate analgesic efficacy and safety of a new transdermal fentanyl patch compared to standard opioid treatment in cancer pain.
Kress HG; Von der Laage D; Hoerauf KH; Nolte T; Heiskanen T; Petersen R; Lundorff L; Sabatowski R; Krenn H; Rosland JH; Saedder EA; Jensen NH
J Pain Symptom Manage; 2008 Sep; 36(3):268-79. PubMed ID: 18538974
[TBL] [Abstract][Full Text] [Related]
17. Comparative efficacy of oral extended-release hydromorphone and immediate-release hydromorphone in patients with persistent moderate to severe pain: two randomized controlled trials.
Grosset AB; Roberts MS; Woodson ME; Shi M; Swanton RE; Reder RF; Buckley BJ
J Pain Symptom Manage; 2005 Jun; 29(6):584-94. PubMed ID: 15963867
[TBL] [Abstract][Full Text] [Related]
18. [Pain reduced and quality of life improved by sustained-release hydromorphone. Results of an observational study].
Sittig HB
MMW Fortschr Med; 2004 Dec; 146(Suppl 3-4):95-8. PubMed ID: 15662898
[TBL] [Abstract][Full Text] [Related]
19. [Pain reduced and quality of life improved by sustained-release hydromorphone. Results of an observational study].
Sittig HB
MMW Fortschr Med; 2004 Dec; 146(49):45. PubMed ID: 15646717
[No Abstract] [Full Text] [Related]
20. Safety and efficacy of hydromorphone as an analgesic alternative to morphine in acute pain: a randomized clinical trial.
Chang AK; Bijur PE; Meyer RH; Kenny MK; Solorzano C; Gallagher EJ
Ann Emerg Med; 2006 Aug; 48(2):164-72. PubMed ID: 16857467
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
